Background: Tau pathology is observed during autopsy in many patients with Parkinson's disease dementia (PDD). Positron emission tomography (PET) imaging using the tracer F-florzolotau has the potential to capture tau accumulation in the living brain.
Objective: The aim was to describe the results of F-florzolotau PET/CT (computed tomography) imaging in patients with PDD.
Methods: Ten patients with PDD, 9 with Parkinson's disease with normal cognition (PD-NC), and 9 age-matched healthy controls (HCs) were enrolled. Clinical assessments and F-florzolotau PET/CT imaging were performed.
Results: F-Florzolotau uptake was significantly higher in the cortical regions of patients with PDD compared with both PD-NC and HCs, especially in the temporal lobe. Notably, F-florzolotau uptake in the occipital lobe of patients with PDD showed a significant correlation with cognitive impairment as reflected by Mini-Mental State Examination (MMSE) scores.
Conclusions: F-Florzolotau PET imaging can effectively capture the occurrence of tau pathology in patients with PDD, which was also linked to MMSE scores. © 2022 International Parkinson and Movement Disorder Society.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.29273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Sapienza University of Rome, Rome, Italy.
Background: Parkinson's disease and Huntington's disease are both neurodegenerative conditions involving the basal ganglia area of the brain. Both conditions can cause symptoms that affect movement. Cognitive decline or dementia can also occur in both.
View Article and Find Full Text PDFComparison of cerebral technetium-99m-ethyl cysteinate dimer perfusion in patients with dementia with Lewy bodies and Parkinson's disease dementia.
Nucl Med Commun
December 2024
Department of Applied Computing, Michigan Technological University.
Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are closely related neurodegenerative conditions within the Lewy body spectrum. The relationship between DLB and PDD remains debated, with ongoing discussion about whether they are distinct diseases or different manifestations of the same disorder. This study aimed to identify differences in cerebral perfusion patterns between DLB and PDD patients.
View Article and Find Full Text PDFAction observation treatment may improve daily living activities and verb recovery in Parkinson's disease-dementia: findings from a preliminary randomized controlled trial.
Front Aging Neurosci
December 2024
Unit of Neurology, INRCA-IRCCS, National Institute of Health and Science on Aging, Ancona, Italy.
Background And Objectives: Action observation treatment (AOT) is a novel rehabilitation approach aimed to the recovery of both motor and linguistic deficits in subjects with brain lesions. The aim of the present randomized controlled study was to assess the benefits of AOT treatment in the activities of daily living (ADLs) and in the linguistic abilities of the patients with Parkinson's disease dementia (PDD) at mild-moderate stage (Hoehn & Yahr's stage scale: 2-3).
Methods: Twenty patients were enrolled and randomly assigned to an experimental group (submitted to AOT) or to a control group.
Automated and quantitative assessment of aortic root based on cardiac computed tomography angiography using a new deep-learning tool: a comparison study.
Quant Imaging Med Surg
December 2024
Zhejiang-Ireland Joint Laboratory for Precision Diagnosis and Treatment of Valvular Heart Diseases, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: Accurate assessment of aortic root is crucial for the preprocedural planning of transcatheter aortic valve replacement (TAVR). A variety software is emerging for the semiautomated or automated measurements during TAVR planning. This study evaluated a new deep-learning (DL) tool based on cardiac computed tomography angiography (CCTA) for fully automatic assessment of aortic root.
View Article and Find Full Text PDFCurrent State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report.
Mol Pharm
December 2024
Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993-0002, United States.
This report summarizes the proceedings for Day 3 of the workshop titled "". This day focused on the current and future drug product quality applications of PBBM from the innovator and generic industries as well as the regulatory agencies perspectives. The presentations, which included several case studies, covered the applications of PBBM in generic drug product development, applications of virtual bioequivalence trials to support formulation bridging and the utility of absorption modeling in clinical pharmacology assessments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!